Auscann Group Holdings Ltd (ASX:AC8)


right-arrow Created with Sketch. -0.001 (-1.2%)
MCAP $36.56M
Last trade 15.44pm 06/12/2021 20mins delayed

Latest Announcements

16/11/2021AC8Auscann Group Holdings Ltd
16/11/2021AC8Auscann Group Holdings Ltd
15/11/2021AC8Auscann Group Holdings Ltd
15/11/2021AC8Auscann Group Holdings Ltd
15/11/2021AC8Auscann Group Holdings Ltd
12/11/2021 Price SensitivePSAC8Auscann Group Holdings Ltd
10/11/2021AC8Auscann Group Holdings Ltd
28/10/2021 Price SensitivePSAC8Auscann Group Holdings Ltd

Company Overview

AusCann Group Holdings Limited is an Australia-based company, which is engaged in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals. The Company focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.

AC8 in the news

AusCann Group (AC8) begins designing a clinical discovery trial to evaluate its…
AusCann (AC8) has submitted its first module of DermaCann to the Australian…
AusCann (AC8) agrees to lease the company’s WA-based research and development (R&D)…
AusCann Group (AC8) has received results from the phase 2A pilot study…

Search Previous Announcements